Novo Nordisk ® ased mortality risk with eight years ting the importance of innovation The unmet need remains large within diabetes Untreated (million) Treated with competitors’ products (million) 463 Treated with Novo Nordisk’ products (million) 101 183 56 30 Diabetic Other OAD population 5 24 Insulin Branded OAD 3 GLP-1 s/complications/stroke.; CVD: Cardiovascular disease; OAD: Oral anti-diabetic; 4 Diabetes Care 2005 Jan;28(1):164-176
Download PDF file